Trial reportDrug design, development and therapy2025
Minimum Effective Volume of Liposomal Bupivacaine for Interscalene Block in Arthroscopic Rotator Cuff Repair: A Prospective, Biased-Coin Up-and-Down Dose-Finding Study.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Analgesic Efficacy and Motor-Sparing Properties of Superior Trunk Block versus Interscalene Brachial Plexus Block with Liposomal Bupivacaine for Shoulder Arthroscopy: A Randomized Controlled Trial.Drug design, development and therapy · 2026Trial
- The ED90 of Liposomal Bupivacaine for Motor-Sparing After Interscalene Brachial Plexus Block: A Dose-Finding Study.Journal of pain research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Establishing the minimum effective volume (MEV90) of liposomal bupivacaine for ultrasound‑guided interscalene brachial plexus block (ISB) is essential to optimize postoperative analgesia and minimize local anesthetic-related side effects in patients undergoing arthroscopic rotator cuff repair. Determining this optimal volume provides a clinically meaningful reference for achieving consistent nerve block success while reducing unnecessary drug exposure and the risk of systemic toxicity. Therefore, the present study aimed to identify the MEV90 of liposomal bupivacaine for ISB in patients undergoing arthroscopic shoulder surgery. Patients and Methods: This dose-finding study enrolled 51 patients scheduled for arthroscopic rotator cuff repair. Using a biased-coin up-and-down sequential design, patients received varying volumes of liposomal bupivacaine for ultrasound-guided ISB. The MEV90 was determined using centered isotonic regression. The occurrence of adverse events was systematically recorded for 72 hours. Results: The MEV90 of liposomal bupivacaine for ISB was 10.0mL (90% CI, 9.3 to 12.5mL). A moderate positive correlation was identified between the time to first analgesic request and the volume of liposomal bupivacaine administered (r = 0.6, P < 0.001). Adverse events within 72 hours following the block included dizziness (7.8%), nausea and vomiting (9.8%), and chest discomfort (3.9%). Conclusion: The MEV90 of liposomal bupivacaine for ultrasound-guided interscalene brachial plexus block in patients undergoing rotator cuff repair surgery was found to be 10.0 mL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.